Canada· CA-DIN-02523566
JAMP GUANFACINE XR
A guanfacine product containing guanfacine (guanfacine hydrochloride), registered in Canada by JAMP PHARMA CORPORATION. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Guanfacine is registered in 14 of 19 countries.
Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Guanfacine · ATC C02AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of guanfacine costs, country by country.
Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Guanfacine · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$7.74
- US United States$0.21 (acquisition cost)
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- GUANFACINE (GUANFACINE HYDROCHLORIDE)
- Manufacturer
- JAMP PHARMA CORPORATION
- Country
- Canada (CA)
- ATC code
- C02AC02
- ATC class
- Guanfacine
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
163 interactions on record for guanfacine.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Guanfacine · interactions on record
163 records
- 30 severe
- 133 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Guanfacine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesguanfacineActavis Pharma, Inc.
- United KingdomGuanfacine 2mg modified-release tabletsAccord-UK Ltd
- CzechiaINTUNIVTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- FinlandIntunivTakeda Pharmaceuticals International AG Ireland Branch
- BelgiumIntuniv 2 mgTakeda Pharmaceuticals International Ireland Branch
- IcelandIntunivTakeda Pharmaceuticals International AG Ireland Branch
- NetherlandsIntuniv 2 mg tabletten met verlengde afgifteTakeda Pharmaceuticals International AG Ireland Branch
- NorwayIntunivTakeda Pharmaceuticals International AG Ireland Branch
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Germany · Guanfacin Neuraxpharm
- United Kingdom (Northern Ireland) · Guanfacine Crescent
- Iceland · Intuniv, Paxneury
- Liechtenstein · Intuniv, Paxneury
- Norway · Intuniv, Paxneury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2676d06-779a-43d6-af8e-e20ff7e31fa7 GET /v1/drugs/d2676d06-779a-43d6-af8e-e20ff7e31fa7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02523566",
"form": "TABLET (EXTENDED-RELEASE)",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "C02AC02",
"schedule": [
"Prescription"
],
"drug_code": "101264",
"strengths": [
"2 MG"
],
"ahfs_class": null,
"substances": [
"GUANFACINE (GUANFACINE HYDROCHLORIDE)"
],
"product_categorization": null
}See everything about guanfacine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.